Calcineurin-nuclear factor of activated T cells pathway-dependent cardiac remodeling in mice deficient in guanylyl cyclase A, a receptor for atrial and brain natriuretic peptides

Circulation

Volumn 111, Issue 23, 2005, Pages 3095-3104

  Tokudome, Takeshi ^a   Horio, Takeshi ^b   Kishimoto, Ichiro ^a,b   Soeki, Takeshi ^a   Mori, Kenji ^a   Kawano, Yuhei ^b   Kohno, Masakazu ^c   Garbers, David L ^d   Nakao, Kazuwa ^e   Kangawa, Kenji ^a  

^a Cardiovascular Research Institute   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c KAGAWA UNIVERSITY   (Japan)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Calcineurin; Fibrosis; Hypertrophy; Natriuretic peptides; Remodeling

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CALCINEURIN; COLLAGEN; FIBRONECTIN; GUANYLATE CYCLASE; HS 142 1; MODULATORY CALCINEURIN INTERACTING PROTEIN 1; PHENYLEPHRINE; TACROLIMUS; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL SIZE; CONTROLLED STUDY; DNA BINDING; ENZYME ACTIVITY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TRANSLOCATION; HEART; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; UPREGULATION;

ANIMALS; ATRIAL NATRIURETIC FACTOR; CALCINEURIN; CARDIOMEGALY; ENZYME ACTIVATION; FIBROSIS; GENE EXPRESSION REGULATION; GUANYLATE CYCLASE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, KNOCKOUT; MUSCLE PROTEINS; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; NFATC TRANSCRIPTION FACTORS; RECEPTORS, ATRIAL NATRIURETIC FACTOR; RNA, MESSENGER; TACROLIMUS;

EID: 20544451579     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.104.510594     Document Type: Article

References (39)

1. Nakao K, Itoh H, Saito Y, Mukoyama M, Ogawa Y. The natriuretic peptide family. Curr Opin Nephrol Hypertens. 1996;5:4-11.
2. Kishimoto I, Garbers DL. Physiological regulation of blood pressure and kidney function by guanylyl cyclase isoforms. Curr Opin Nephrol Hypertens. 1997;6:58-63.
3. Lin X, Hänze J, Heese F, Sodmann R, Lang RE. Gene expression of natriuretic peptide in myocardial cells. Circ Res. 1995;77:750-758.
4. Horio T, Tokudome T, Maki T, Yoshihara F, Suga S, Nishikimi T, Kojima M, Kawano Y, Kangawa K. Gene expression, secretion, and autocrine action of C-type natriuretic peptide in cultured adult rat cardiac fibroblasts. Endocrinology. 2003;144:2279-2284.
5. Tokudome T, Horio T, Soeki T, Mori K, Kishimoto I, Suga S, Yoshihara F, Kawano Y, Kohno M, Kangawa K. Inhibitory effect of C-type natriuretic peptide (CNP) on cultured cardiac myocyte hypertrophy: interference between CNP and endothelin-1 signaling pathways. Endocrinology. 2004;145:2131-2140.
6. Horio T, Nishikimi T, Yoshihara T, Matsuo H, Takishita S, Kangawa K. Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. Hypertension. 2000;35:19-24.
7. Lopez MJ, Wong SK, Kishimoto I, Dubois S, Mach V, Friesen J, Garbers DL, Beuve A. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature. 1995;378:65-68.
8. Oliver PM, Fox JE, Kim R, Rockman HA, Kim HS, Reddick RT, Pandey KN, Milgram SL, Smithies O, Maeda N. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci USA. 1997;94:14730-14735.
9. Garbers DL, Dubois SK. The molecular basis of hypertension. Annu Rev Biochem. 1999;68:127-155.
10. Knowles JW, Esposito G, Mao L, Hagaman JR, Fox JE, Smithies O, Rockman HA, Maeda N. Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J Clin Invest. 2001;107:975-984.
11. Kishimoto I, Rossi K, Garbers DL. A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc Natl Acad Sci U S A. 2001;98:2703-2706.
12. Holtwick R, Eickels MV, Skryabin BV, Baba HA, Bubikat A, Begrow F, Schneider MD, Garbers DL, Kuhn M. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest. 2003;111: 1399-1407.
13. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93:215-228.
14. Vega RB, Bassel-Duby R, Olson EN. Control of cardiac growth and function by calcineurin signaling. J Biol Chem. 2003;278:36981-36984.
15. Klee CB, Ren H, Wang X. Regulation of the calmodulin-stimulated protein phosphatase, calcineurin. J Biol Chem. 1998;273:13367-13370.
16. Crabtree GR. Calcium, calcineurin, and the control of transcription. J Biol Chem. 2001;276:2313-2316.
17. 2+ response amplitude and duration. Nature. 1997;386:855-858.
18. Molkentin JD. Calcineurin and beyond: cardiac hypertrophic signaling. Circ Res. 2000;87:731-738.
19. Shimoyama M, Hayashi D, Zou Y, Takimoto E, Mizukami M, Monzen K, Kudoh S, Hiroi Y, Yazaki Y, Nagai R, Komuro I. Calcineurin inhibitor attenuates the development and induces the regression of cardiac hypertrophy in rats with salt-sensitive hypertension. Circulation. 2000;102: 1996-2004.
20. Sakata Y, Masuyama T, Yamamoto K, Nishikawa N, Yamamoto H, Kondo H, Ono K, Otsu K, Kuzuya T, Miwa T, Takeda H, Miyamoto E, Hori M. Calcineurin inhibitor attenuates left ventricular hypertrophy, leading to prevention of heart failure in hypertensive rats. Circulation. 2000;102:2269-2275.
21. Zou Y, Hiroi Y, Uozumi H, Takimoto E, Toko H, Zhu W, Kudoh S, Mizukami M, Shimoyama M, Shibasaki F, Nagai R, Yazaki Y, Komuro I. Calcineurin plays a critical role in the development of pressure overload-induced cardiac hypertrophy. Circulation. 2001;104:97-101.
22. Takeda Y, Yoneda T, Demura M, Usukura M, Mabuchi H. Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy. Circulation. 2002;105:677-679.
23. 1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats. Hypertension. 2002;40:168-174.
24. Blumenthal DK, Takio K, Hansen RS, Krebs EG. Dephosphorylation of cAMP-dependent protein kinase regulatory subunit (type II) by calmodulin-dependent protein phosphatase. J Biol Chem. 1986;261:8140-8145.
25. Fruman DA, Klee CB, Bierer BE, Burakoff SJ. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK506 and cyclosporin A. Proc Natl Acad Sci USA. 1992;89:3686-3690.
26. Zheng JS, Boluyt MO, O'Neill L, Crow MT, Lakatta EG. Extracellular ATP induces immediate-early gene expression but not cellular hypertrophy in neonatal cardiac myocytes. Circ Res. 1994;74:1034-1041.
27. Harada M, Itoh H, Nakagawa O, Ogawa Y, Miyamoto Y, Kuwahara K, Ogawa E, Igaki T, Yamashita J, Masuda I, Yoshimasa T, Tanaka I, Saito Y, Nakao K. Significance of ventricular myocytes and nonmyocytes interaction during cardiocyte hypertrophy: evidence for endothelin-1 as a paracrine hypertrophic factor from cardiac nonmyocytes. Circulation. 1997;96:3737-3744.
28. Wilkins BJ, De Windt LJ, Bueno OF, Braz JC, Glascock BJ, Kimball TF, Molkentin JD. Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth. Mol Cell Biol. 2002;22:7603-7613.
29. Thibault G, Amiri F, Garcia R. Regulation of natriuretic peptide secretion by the heart. Annu Rev Physiol. 1999;61:193-217.
30. De Bold AJ, Bruneau BG, Kuroski de Bold ML. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res. 1996; 31:7-18.
31. Molkentin JD, Olson EN. GATA4: a novel transcriptional regulator of cardiac hypertrophy? Circulation. 1997;96:3833-3835.
32. Li Y, Kishimoto I, Saito Y, Harada M, Kuwahara K, Izumi T, Takahashi N, Kawakami R, Tanimoto K, Nakagawa Y, Nakanishi M, Adachi Y, Garbers DL, Fukamizu A, Nakao K. Guanylyl cyclase-A inhibits angiotensin II type 1A receptor-mediated cardiac remodeling, an endogenous protective mechanism in the heart. Circulation. 2002;106:1722-1728.
33. Kuhn M. Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A. Circ Res. 2003;93:700-709.
34. Fiedler B, Lohmann SM, Smolenski A, Linnemüller S, Pieske B, Schröder F, Molkentin JD, Drexler H, Wollert KC. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci U S A. 2002;99: 11363-11368.
35. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83: 1849-1865.
36. Gooch JL, Gorin Y, Zhang BX, Abboud HE. Involvement of calcineurin in transforming growth factor-β-mediated regulation of extracellular matrix accumulation. J Biol Chem. 2004;279:15561-15570.
37. Ravingerova T, Barancik M, Strniskova M. Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology. Mol Cell Biochem. 2003;247:127-138.
38. Ishizuka S, Sievers RE, Zhu BQ, Rodrigo MC, Joho S, Foster E, Simpson PC, Grossman W. New technique for measurement of left ventricular pressure in conscious mice. Am J Physiol Heart Circ Physiol. 2004;286: H1208-H1215.
39. Nakayama T, Soma M, Takahashi Y, Rehemudula D, kanmatsuse K, Furuya K. Functional deletion mutation of the 5′-flanking region of type A human natriuretic peptide receptor gene and its association with essential hypertension and left ventricular hypertrophy in the Japanese. Circ Res. 2000;86:841-845.